MX393759B - Suspensiones inyectables - Google Patents

Suspensiones inyectables

Info

Publication number
MX393759B
MX393759B MX2019007504A MX2019007504A MX393759B MX 393759 B MX393759 B MX 393759B MX 2019007504 A MX2019007504 A MX 2019007504A MX 2019007504 A MX2019007504 A MX 2019007504A MX 393759 B MX393759 B MX 393759B
Authority
MX
Mexico
Prior art keywords
suspensions
injectable suspensions
pregnan
micronized
beta
Prior art date
Application number
MX2019007504A
Other languages
English (en)
Other versions
MX2019007504A (es
Inventor
Björn Norrlind
Karol Horvath
Magnus Brisander
Original Assignee
Asarina Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asarina Pharma Ab filed Critical Asarina Pharma Ab
Publication of MX2019007504A publication Critical patent/MX2019007504A/es
Publication of MX393759B publication Critical patent/MX393759B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0004—Crystallisation cooling by heat exchange
    • B01D9/0009—Crystallisation cooling by heat exchange by direct heat exchange with added cooling fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Thermal Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nutrition Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a suspensiones asépticas, físicamente estables e inyectables a través de una aguja 25G o más delgada, que comprende partículas cristalinas, no micronizadas de 3-beta-hidroxi-5- lfa-pregnan-20-ona, una mezcla de acilgliceroles y colesterol, procedimientos para preparar 3-beta-hidroxi 5-alfa-pregnan-20-ona cristalina no micronizada, adecuada para tales suspensiones, así como los métodos para fabricar dichas suspensiones.
MX2019007504A 2017-01-09 2018-01-09 Suspensiones inyectables MX393759B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1750008 2017-01-09
PCT/EP2018/050453 WO2018127601A1 (en) 2017-01-09 2018-01-09 Injectable suspensions

Publications (2)

Publication Number Publication Date
MX2019007504A MX2019007504A (es) 2020-07-29
MX393759B true MX393759B (es) 2025-03-24

Family

ID=61002996

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007504A MX393759B (es) 2017-01-09 2018-01-09 Suspensiones inyectables

Country Status (20)

Country Link
US (3) US10933014B2 (es)
EP (2) EP4530290A3 (es)
JP (2) JP7278949B2 (es)
KR (1) KR102552425B1 (es)
CN (1) CN110167532B (es)
AU (1) AU2018206222B2 (es)
CA (1) CA3046128A1 (es)
DK (1) DK3565528T3 (es)
ES (1) ES3032634T3 (es)
FI (1) FI3565528T3 (es)
HR (1) HRP20250605T1 (es)
HU (1) HUE071954T2 (es)
IL (1) IL267884B2 (es)
LT (1) LT3565528T (es)
MX (1) MX393759B (es)
PT (1) PT3565528T (es)
RS (1) RS67063B1 (es)
RU (1) RU2019116165A (es)
SI (1) SI3565528T1 (es)
WO (1) WO2018127601A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3565528T3 (da) * 2017-01-09 2025-05-26 Relmada Therapeutics Inc Injicerbare suspensioner
CN113633611B (zh) * 2020-05-11 2024-08-27 鲁南制药集团股份有限公司 一种己酸羟孕酮混悬注射液及其制备方法
US20250375571A1 (en) * 2022-10-27 2025-12-11 Spiderwort Biotechnologies Inc. Methods and devices for removing agglomerations from of a viscous material

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02286625A (ja) * 1989-04-27 1990-11-26 Dainippon Pharmaceut Co Ltd 注射用持続性製剤
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
WO1999045931A1 (en) 1998-03-11 1999-09-16 Baeckstroem Torbjoern Epiallopregnanolone in the treatment of cns disorders
US20050202505A1 (en) * 2001-08-22 2005-09-15 Philipp Floersheim Method to identify modulators for human 3alpha-hydroxysteroid dehydrogenase
SE0104423D0 (sv) * 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
EP1868593A2 (en) 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
EP2260052A4 (en) 2008-02-26 2013-01-16 Univ Emory STEROIDANALOGA FOR NEUROPROTEKTION
SI2341905T2 (sl) 2008-09-04 2024-02-29 Amylin Pharmaceuticals, Llc Formulacije s podaljšanim sproščanjem z uporabo brezvodnih nosilcev
AU2010264670A1 (en) * 2009-06-24 2012-01-19 Merck Sharp & Dohme B.V. Injectable formulations containing asenapine and method of treatment using same
US8195407B2 (en) * 2009-10-09 2012-06-05 GM Global Technology Operations LLC Online method to estimate hydrogen concentration estimation in fuel cell systems at shutdown and startup
MX2012008257A (es) 2010-01-14 2012-11-21 Umecrine Mood Ab Una composicion farmaceutica que comprende 3-beta-hidroxi-5-alfa-p regnan-20-ona con propiedades mejoradas de almacenamiento y solubilidad.
EP2385637B1 (en) * 2010-05-07 2013-12-25 Telefonaktiebolaget LM Ericsson (Publ) Methods and devices for modulating a signal
US9802926B2 (en) * 2014-06-20 2017-10-31 Aviragen Therapeutics, Inc. Anhydrous crystalline free base form of 6-{2-[1 -(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole
DK3565528T3 (da) * 2017-01-09 2025-05-26 Relmada Therapeutics Inc Injicerbare suspensioner

Also Published As

Publication number Publication date
SI3565528T1 (sl) 2025-10-30
US20190350838A1 (en) 2019-11-21
PT3565528T (pt) 2025-06-04
EP4530290A3 (en) 2025-06-25
IL267884B2 (en) 2024-04-01
US10933014B2 (en) 2021-03-02
US20210100736A1 (en) 2021-04-08
IL267884B1 (en) 2023-12-01
AU2018206222A1 (en) 2019-06-13
RU2019116165A (ru) 2021-02-09
CN110167532B (zh) 2023-02-21
LT3565528T (lt) 2025-06-25
FI3565528T3 (fi) 2025-05-25
CN110167532A (zh) 2019-08-23
JP7278949B2 (ja) 2023-05-22
IL267884A (en) 2019-09-26
WO2018127601A1 (en) 2018-07-12
DK3565528T3 (da) 2025-05-26
EP3565528A1 (en) 2019-11-13
KR102552425B1 (ko) 2023-07-06
JP2022188127A (ja) 2022-12-20
HUE071954T2 (hu) 2025-10-28
US20250041206A1 (en) 2025-02-06
EP4530290A2 (en) 2025-04-02
RU2019116165A3 (es) 2021-03-01
EP3565528B1 (en) 2025-02-19
CA3046128A1 (en) 2018-07-12
ES3032634T3 (en) 2025-07-22
RS67063B1 (sr) 2025-08-29
AU2018206222B2 (en) 2023-04-13
BR112019012959A2 (pt) 2019-11-26
MX2019007504A (es) 2020-07-29
JP2020514250A (ja) 2020-05-21
KR20190104361A (ko) 2019-09-09
HRP20250605T1 (hr) 2025-07-18

Similar Documents

Publication Publication Date Title
MX2017004141A (es) Metodo para la produccion de material de tabaco homogeneizado.
MX2017004579A (es) Estructuras fibrosas solubles y metodos para fabricarlas.
MX2017004617A (es) Variantes estabilizadas de alfa amilasa y su uso.
GB2546432A (en) Apertured fibrous structures and methods for making same
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
MX2019005250A (es) Componentes para articulos de calzado que incluyen componentes textiles, ligeros soportados en forma selectiva.
EA201691448A1 (ru) Гибридосомы, содержащие их композиции, способы их получения и их применения
PH12020500329A1 (en) Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
MX2016014197A (es) 4-fenilpiperidinas sustituidas, su preparacion y uso.
WO2016033437A3 (en) Polyethers, polyamines, polythioethers, and methods for making same
PH12017500566A1 (en) Improved polypropylene fibers, methods for producing the same and uses thereof for the production of fiber cement products
BR112018013180A2 (pt) partículas zeolíticas com dimensões nanométricas e processo para produção das mesmas
CY1122506T1 (el) Κρυσταλλικη μορφη της ενωσης (s)-3-{4-[5-(2-κυκλοπεντυλ-6- μεθοξυ- πυριδιν-4- υλ)-[1,2,4]οξαδιαζολ-3- υλ]-2- αιθυλ-6-μεθυλ- φαινοξυ}- προπανο-1,2- διολη
PH12016501613B1 (en) Pyrazines modulators of gpr6
CY1124164T1 (el) Καινοτομος παρασκευη και κρυσταλλωση της ιοσιμενολης
CY1120185T1 (el) Υποκατεστημενα πυριδινικα παραγωγα χρησιμα ως αναστολεις c-fms κινασης
MX393759B (es) Suspensiones inyectables
IN2014MU00675A (es)
MX2015009330A (es) Reordenamiento del virus de influenza.
WO2016055647A3 (fr) Procede de preparation de plasma universel
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
MX2016013439A (es) Formas solidas de un compuesto farmaceuticamente activo.
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
EA201691203A1 (ru) Твёрдые формы тенофовира
WO2014128728A3 (en) Solid forms of cabazitaxel and processes for preparation thereof